M. Kulyk & Associates LLC Purchases Shares of 2,159 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

M. Kulyk & Associates LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,159 shares of the biopharmaceutical company’s stock, valued at approximately $1,538,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Amundi grew its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% in the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after acquiring an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $127,489,000. KBC Group NV grew its holdings in shares of Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after acquiring an additional 102,198 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $65,180,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.3 %

Shares of REGN stock opened at $707.51 on Friday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market cap of $77.35 billion, a P/E ratio of 18.48, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The stock has a 50 day simple moving average of $696.12 and a 200 day simple moving average of $851.05. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $11.86 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on REGN. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Citigroup reduced their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Robert W. Baird reduced their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.